LAG‐3 : recent developments in combinational therapies in cancer
Cancer Science · 2024-08 · 115 (8) · 2494-2505
DOI: 10.1111/cas.16205 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Cancer Science, online erschienen am 04.05.2024. Verfasst von Aude Chavanton und 4 weiteren Autor:innen. Beteiligte Einrichtung: INSERM, UMR 1231, Laboratoire d'Excellence LipSTIC and « Equipe labellisée par la Ligue Nationale contre le Cancer », Dijon, France. Hauptthemen laut MEDLINE: Lymphocyte Activation Gene 3 Protein, Neoplasms, Immune Checkpoint Inhibitors, Antigens, CD. Die Arbeit wurde bisher 38-mal zitiert (Crossref) und nennt 114 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: FEDER, Ruban Rose Fondation, Conseil régional de Bourgogne-Franche-Comté.
Abstract (Originalsprache)
The study of anticancer immune responses and in particular the action of immune checkpoint inhibitors that overcome T cell inhibition has revolutionized metastatic patients' care. Unfortunately, many patients are resistant to these innovative immunotherapies. Over the last decade, several immune checkpoint inhibitors, currently available in the clinic, have been developed, such as anti‐PD‐1/PD‐L1 or anti‐CTLA‐4. More recently, other immune checkpoints have been characterized, among them lymphocyte activation gene 3 (LAG‐3). LAG‐3 has been the subject of numerous therapeutic studies and may be involved in cancer‐associated immune resistance phenomena. This review summarizes the latest knowledge on LAG‐3 as an immunotherapeutic target, particularly in combination with standard or innovative therapies. Indeed, many studies are looking at combining LAG‐3 inhibitors with chemotherapeutic, immunotherapeutic, radiotherapeutic treatments, or adoptive cell therapies to potentiate their antitumor effects and/or to overcome patients' resistance. We will particularly focus on the association therapies that are currently in phase III clinical trials and innovative combinations in preclinical phase. These new discoveries highlight the possibility of developing other types of therapeutic combinations currently unavailable in the clinic, which could broaden the therapeutic spectrum of personalized medicine.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- INSERM, UMR 1231, Laboratoire d'Excellence LipSTIC and « Equipe labellisée par la Ligue Nationale contre le Cancer », Dijon, France.
- Faculty of Medicine, Université de Bourgogne, Dijon, France.
- Center for Cancer Georges-François Leclerc, Dijon, France.
ORCID-Profile: Carmen Garrido
Förderung
- FEDER
- Ruban Rose Fondation
- Conseil régional de Bourgogne-Franche-Comté
- Institut National contre le Cancer
- European Regional Development Fund
Zitieren
APA
Chavanton, A., Mialhe, F., Abrey, J., Baeza Garcia, A., & Garrido, C. (2024). LAG‐3 : recent developments in combinational therapies in cancer. Cancer Science, 115(8), 2494-2505. https://doi.org/10.1111/cas.16205
Vancouver
Chavanton A, Mialhe F, Abrey J, Baeza Garcia A, Garrido C. LAG‐3 : recent developments in combinational therapies in cancer. Cancer Science. 2024;115(8):2494-2505. doi:10.1111/cas.16205
BibTeX
@article{Chavanton2024,
author = {Chavanton, Aude and Mialhe, Flavie and Abrey, Jimena and Baeza Garcia, Alvaro and Garrido, Carmen},
title = {LAG‐3 : recent developments in combinational therapies in cancer},
journal = {Cancer Science},
year = {2024},
volume = {115},
number = {8},
pages = {2494--2505},
doi = {10.1111/cas.16205}
}
EUVIMED